CA2339301A1 - Hdpbo81 nucleic acids and polypeptides - Google Patents
Hdpbo81 nucleic acids and polypeptides Download PDFInfo
- Publication number
- CA2339301A1 CA2339301A1 CA002339301A CA2339301A CA2339301A1 CA 2339301 A1 CA2339301 A1 CA 2339301A1 CA 002339301 A CA002339301 A CA 002339301A CA 2339301 A CA2339301 A CA 2339301A CA 2339301 A1 CA2339301 A1 CA 2339301A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gene
- polypeptides
- tissues
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 21
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 358
- 229920001184 polypeptide Polymers 0.000 title claims description 354
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 354
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 559
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 248
- 239000013598 vector Substances 0.000 claims abstract description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 297
- 102000040430 polynucleotide Human genes 0.000 claims description 297
- 239000002157 polynucleotide Substances 0.000 claims description 296
- 230000014509 gene expression Effects 0.000 claims description 141
- 239000000047 product Substances 0.000 claims description 104
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- 230000004071 biological effect Effects 0.000 claims description 58
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 49
- 239000012472 biological sample Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 239000002299 complementary DNA Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 34
- 108091026890 Coding region Proteins 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 434
- 210000004027 cell Anatomy 0.000 description 254
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 248
- 235000018102 proteins Nutrition 0.000 description 239
- 208000035475 disorder Diseases 0.000 description 196
- 238000011282 treatment Methods 0.000 description 84
- 206010028980 Neoplasm Diseases 0.000 description 82
- 238000003745 diagnosis Methods 0.000 description 70
- 210000001124 body fluid Anatomy 0.000 description 67
- 239000000523 sample Substances 0.000 description 67
- 230000004069 differentiation Effects 0.000 description 64
- 201000010099 disease Diseases 0.000 description 52
- 238000009826 distribution Methods 0.000 description 46
- 239000003795 chemical substances by application Substances 0.000 description 44
- 201000011510 cancer Diseases 0.000 description 41
- 230000035755 proliferation Effects 0.000 description 40
- 102000005962 receptors Human genes 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 40
- 239000003153 chemical reaction reagent Substances 0.000 description 38
- 230000002265 prevention Effects 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 36
- 239000012530 fluid Substances 0.000 description 34
- 230000001900 immune effect Effects 0.000 description 34
- 230000003993 interaction Effects 0.000 description 34
- 238000001514 detection method Methods 0.000 description 33
- 208000026278 immune system disease Diseases 0.000 description 33
- 238000009169 immunotherapy Methods 0.000 description 33
- 210000002381 plasma Anatomy 0.000 description 33
- 239000000439 tumor marker Substances 0.000 description 33
- 210000002700 urine Anatomy 0.000 description 33
- 235000015872 dietary supplement Nutrition 0.000 description 32
- 210000001179 synovial fluid Anatomy 0.000 description 32
- 239000003446 ligand Substances 0.000 description 31
- 210000002751 lymph Anatomy 0.000 description 30
- 210000000130 stem cell Anatomy 0.000 description 30
- 210000000349 chromosome Anatomy 0.000 description 28
- 230000002062 proliferating effect Effects 0.000 description 28
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 27
- 239000008280 blood Substances 0.000 description 26
- 230000002163 immunogen Effects 0.000 description 26
- 230000006907 apoptotic process Effects 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 206010039073 rheumatoid arthritis Diseases 0.000 description 25
- 230000024245 cell differentiation Effects 0.000 description 24
- 230000001413 cellular effect Effects 0.000 description 24
- 208000014674 injury Diseases 0.000 description 24
- 230000033228 biological regulation Effects 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 238000013519 translation Methods 0.000 description 21
- 206010020751 Hypersensitivity Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 230000006399 behavior Effects 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 20
- 208000016192 Demyelinating disease Diseases 0.000 description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 description 19
- 201000004681 Psoriasis Diseases 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 230000001605 fetal effect Effects 0.000 description 19
- 230000003463 hyperproliferative effect Effects 0.000 description 19
- 210000000987 immune system Anatomy 0.000 description 19
- 208000032839 leukemia Diseases 0.000 description 19
- 208000029462 Immunodeficiency disease Diseases 0.000 description 18
- 230000003394 haemopoietic effect Effects 0.000 description 17
- 230000001537 neural effect Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 16
- 230000001850 reproductive effect Effects 0.000 description 16
- 238000011144 upstream manufacturing Methods 0.000 description 16
- 230000005965 immune activity Effects 0.000 description 15
- 230000007574 infarction Effects 0.000 description 15
- 230000019491 signal transduction Effects 0.000 description 15
- 208000035473 Communicable disease Diseases 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 14
- 206010039710 Scleroderma Diseases 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 206010003246 arthritis Diseases 0.000 description 13
- 208000006673 asthma Diseases 0.000 description 13
- 230000005784 autoimmunity Effects 0.000 description 13
- 238000005755 formation reaction Methods 0.000 description 13
- 208000030507 AIDS Diseases 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 208000021386 Sjogren Syndrome Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 230000008733 trauma Effects 0.000 description 12
- 208000002874 Acne Vulgaris Diseases 0.000 description 11
- 206010012305 Demyelination Diseases 0.000 description 11
- 208000009329 Graft vs Host Disease Diseases 0.000 description 11
- 206010018691 Granuloma Diseases 0.000 description 11
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 11
- 206010040047 Sepsis Diseases 0.000 description 11
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 11
- 206010000496 acne Diseases 0.000 description 11
- 230000030741 antigen processing and presentation Effects 0.000 description 11
- 230000001363 autoimmune Effects 0.000 description 11
- 230000003542 behavioural effect Effects 0.000 description 11
- 210000000601 blood cell Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 208000007475 hemolytic anemia Diseases 0.000 description 11
- 230000009610 hypersensitivity Effects 0.000 description 11
- 230000036737 immune function Effects 0.000 description 11
- 230000008105 immune reaction Effects 0.000 description 11
- 208000000509 infertility Diseases 0.000 description 11
- 230000036512 infertility Effects 0.000 description 11
- 231100000535 infertility Toxicity 0.000 description 11
- 208000004235 neutropenia Diseases 0.000 description 11
- 230000007261 regionalization Effects 0.000 description 11
- 230000024833 regulation of cytokine production Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 11
- 208000037816 tissue injury Diseases 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 10
- 206010029379 Neutrophilia Diseases 0.000 description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- 208000007502 anemia Diseases 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000009826 neoplastic cell growth Effects 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 230000008929 regeneration Effects 0.000 description 10
- 238000011069 regeneration method Methods 0.000 description 10
- 229910052725 zinc Inorganic materials 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 206010002329 Aneurysm Diseases 0.000 description 9
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 206010012289 Dementia Diseases 0.000 description 9
- 208000023105 Huntington disease Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 201000009906 Meningitis Diseases 0.000 description 9
- 206010033864 Paranoia Diseases 0.000 description 9
- 208000027099 Paranoid disease Diseases 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 230000007815 allergy Effects 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 230000013020 embryo development Effects 0.000 description 9
- 230000002124 endocrine Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000011275 oncology therapy Methods 0.000 description 9
- 208000033808 peripheral neuropathy Diseases 0.000 description 9
- 230000001817 pituitary effect Effects 0.000 description 9
- 201000000980 schizophrenia Diseases 0.000 description 9
- 206010003805 Autism Diseases 0.000 description 8
- 208000020706 Autistic disease Diseases 0.000 description 8
- 206010010356 Congenital anomaly Diseases 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 8
- 208000012239 Developmental disease Diseases 0.000 description 8
- 208000017701 Endocrine disease Diseases 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 206010026749 Mania Diseases 0.000 description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 8
- 208000028017 Psychotic disease Diseases 0.000 description 8
- 206010058571 Spinal cord infarction Diseases 0.000 description 8
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 8
- 208000000323 Tourette Syndrome Diseases 0.000 description 8
- 208000016620 Tourette disease Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 210000004381 amniotic fluid Anatomy 0.000 description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 206010014599 encephalitis Diseases 0.000 description 8
- 230000004968 inflammatory condition Effects 0.000 description 8
- 201000003723 learning disability Diseases 0.000 description 8
- 230000036244 malformation Effects 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 208000019906 panic disease Diseases 0.000 description 8
- 230000008447 perception Effects 0.000 description 8
- 208000027232 peripheral nervous system disease Diseases 0.000 description 8
- 230000007958 sleep Effects 0.000 description 8
- 208000020431 spinal cord injury Diseases 0.000 description 8
- 102000012545 EGF-like domains Human genes 0.000 description 7
- 108050002150 EGF-like domains Proteins 0.000 description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- 208000031220 Hemophilia Diseases 0.000 description 7
- 208000009292 Hemophilia A Diseases 0.000 description 7
- 206010061598 Immunodeficiency Diseases 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 7
- 206010040070 Septic Shock Diseases 0.000 description 7
- 208000000453 Skin Neoplasms Diseases 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 229940030225 antihemorrhagics Drugs 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 230000001659 chemokinetic effect Effects 0.000 description 7
- 230000003399 chemotactic effect Effects 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 230000035558 fertility Effects 0.000 description 7
- 210000003754 fetus Anatomy 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000000025 haemostatic effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000007813 immunodeficiency Effects 0.000 description 7
- 230000003308 immunostimulating effect Effects 0.000 description 7
- 230000001861 immunosuppressant effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 210000003041 ligament Anatomy 0.000 description 7
- 208000025113 myeloid leukemia Diseases 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 230000000849 parathyroid Effects 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 230000017363 positive regulation of growth Effects 0.000 description 7
- 230000011373 regulation of behavior Effects 0.000 description 7
- 230000018406 regulation of metabolic process Effects 0.000 description 7
- 230000036303 septic shock Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 210000002435 tendon Anatomy 0.000 description 7
- 230000002537 thrombolytic effect Effects 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108010085895 Laminin Proteins 0.000 description 6
- 102000007547 Laminin Human genes 0.000 description 6
- 206010029098 Neoplasm skin Diseases 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 208000026872 Addison Disease Diseases 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000014311 Cushing syndrome Diseases 0.000 description 5
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 5
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 5
- 208000000038 Hypoparathyroidism Diseases 0.000 description 5
- 206010021067 Hypopituitarism Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 108090001033 Sulfotransferases Proteins 0.000 description 5
- 102000004896 Sulfotransferases Human genes 0.000 description 5
- 206010042971 T-cell lymphoma Diseases 0.000 description 5
- 210000004404 adrenal cortex Anatomy 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000002249 digestive system Anatomy 0.000 description 5
- 210000000777 hematopoietic system Anatomy 0.000 description 5
- 230000013632 homeostatic process Effects 0.000 description 5
- 208000003532 hypothyroidism Diseases 0.000 description 5
- 230000002989 hypothyroidism Effects 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000004031 neuronal differentiation Effects 0.000 description 5
- 230000006576 neuronal survival Effects 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 230000005062 synaptic transmission Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 210000001685 thyroid gland Anatomy 0.000 description 5
- 210000003606 umbilical vein Anatomy 0.000 description 5
- 102000034263 Amino acid transporters Human genes 0.000 description 4
- 108050005273 Amino acid transporters Proteins 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010074307 Phosphoacetylglucosamine mutase Proteins 0.000 description 4
- 102100024440 Phosphoacetylglucosamine mutase Human genes 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 4
- 208000017568 chondrodysplasia Diseases 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 210000000750 endocrine system Anatomy 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 208000018706 hematopoietic system disease Diseases 0.000 description 4
- 230000033444 hydroxylation Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 210000004994 reproductive system Anatomy 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 3
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 3
- 102000009569 Phosphoglucomutase Human genes 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000017504 atelosteogenesis type II Diseases 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000006359 hepatoblastoma Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000001582 osteoblastic effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 108091000115 phosphomannomutase Proteins 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 208000005333 pulmonary edema Diseases 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 2
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 2
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 2
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 2
- 101710189782 Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 208000007984 Female Infertility Diseases 0.000 description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 2
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 2
- 101000775595 Homo sapiens Carbohydrate sulfotransferase 10 Proteins 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 108091006232 SLC7A5 Proteins 0.000 description 2
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- AKXIYZBZYOTHPH-SKSRJFFGSA-N beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O)[C@H](O2)C(O)=O)O)[C@@H](O)[C@@H](CO)O1 AKXIYZBZYOTHPH-SKSRJFFGSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000002802 cardiorespiratory effect Effects 0.000 description 2
- -1 cationic amino acids Chemical class 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000009547 development abnormality Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 208000023965 endometrium neoplasm Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002458 fetal heart Anatomy 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 208000010544 human prion disease Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000015625 metaphyseal chondrodysplasia Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 102000044158 nucleic acid binding protein Human genes 0.000 description 2
- 108700020942 nucleic acid binding protein Proteins 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000004946 small molecule transport Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- YYLQUHNPNCGKJQ-NHYDCYSISA-N (3R)-3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)[C@@H](O)C(O)=O YYLQUHNPNCGKJQ-NHYDCYSISA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101150076315 AGM1 gene Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000020007 Autosomal agammaglobulinemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100123358 Caenorhabditis elegans his-54 gene Proteins 0.000 description 1
- 101100177112 Caenorhabditis elegans his-70 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102100032145 Carbohydrate sulfotransferase 10 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000959671 Chenopodium leaf curl virus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010067248 Congenital naevus Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 108010049375 HNK-1 sulfotransferase Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000802660 Homo sapiens Histo-blood group ABO system transferase Proteins 0.000 description 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001008568 Homo sapiens Laminin subunit beta-1 Proteins 0.000 description 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 1
- 101000833350 Homo sapiens Phosphoacetylglucosamine mutase Proteins 0.000 description 1
- 101000614345 Homo sapiens Prolyl 4-hydroxylase subunit alpha-1 Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010031311 Intramolecular Transferases Proteins 0.000 description 1
- 102000005385 Intramolecular Transferases Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 101100449303 Lactiplantibacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1) gpmA1 gene Proteins 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100122010 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) glmM gene Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 201000009139 Mongolian Spot Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100490848 Mus musculus Alg2 gene Proteins 0.000 description 1
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101100463092 Mus musculus Pdcd6 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 101150085490 PGM2 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100034785 Programmed cell death protein 6 Human genes 0.000 description 1
- 101710089369 Programmed cell death protein 6 Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101000775588 Rattus norvegicus Carbohydrate sulfotransferase 10 Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108091006236 SLC7A7 Proteins 0.000 description 1
- FYDVFEYWHBZMFQ-UHFFFAOYSA-N SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS Chemical compound SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS FYDVFEYWHBZMFQ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 108010068068 Transcription Factor TFIIIA Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000002575 demyelinative effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 102000051283 human LAMB1 Human genes 0.000 description 1
- 102000051365 human P4HA1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 108010090909 laminin gamma 1 Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 201000004151 lysinuric protein intolerance Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000004169 miliaria rubra Diseases 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000020043 port wine Nutrition 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 108700017509 rat Fbxo2 Proteins 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9465798P | 1998-07-30 | 1998-07-30 | |
| US9548698P | 1998-08-05 | 1998-08-05 | |
| US9545598P | 1998-08-06 | 1998-08-06 | |
| US9545498P | 1998-08-06 | 1998-08-06 | |
| US9631998P | 1998-08-12 | 1998-08-12 | |
| US60/096,319 | 1998-08-12 | ||
| US60/095,486 | 1998-08-12 | ||
| US60/094,657 | 1998-08-12 | ||
| US60/095,455 | 1998-08-12 | ||
| US60/095,454 | 1998-08-12 | ||
| PCT/US1999/017130 WO2000006698A1 (en) | 1998-07-30 | 1999-07-29 | 98 human secreted proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2339301A1 true CA2339301A1 (en) | 2000-02-10 |
Family
ID=27536719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002339301A Abandoned CA2339301A1 (en) | 1998-07-30 | 1999-07-29 | Hdpbo81 nucleic acids and polypeptides |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6476195B1 (enExample) |
| EP (1) | EP1100869A4 (enExample) |
| JP (1) | JP2002521055A (enExample) |
| AU (1) | AU5134799A (enExample) |
| CA (1) | CA2339301A1 (enExample) |
| WO (1) | WO2000006698A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030166107A1 (en) * | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030049751A1 (en) * | 1997-09-18 | 2003-03-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030050240A1 (en) * | 1997-10-17 | 2003-03-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7067636B2 (en) * | 1998-05-06 | 2006-06-27 | Genentech, Inc. | Anti-pro 1017 antibodies |
| US7339033B2 (en) * | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
| AU2003204357B2 (en) * | 1998-09-01 | 2006-03-30 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| US7414112B2 (en) * | 1998-10-08 | 2008-08-19 | Genentech, Inc. | Antibodies to PRO1550 polypeptides |
| WO2000039296A1 (en) | 1998-12-23 | 2000-07-06 | Immunex Corporation | Lectin s3939 dna and polypeptides |
| US7109292B2 (en) * | 1999-03-08 | 2006-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1171597A2 (en) * | 1999-04-12 | 2002-01-16 | Agensys, Inc. | Prostate-restricted gene 30p3c8 expressed in prostate cancer |
| JP2002543838A (ja) * | 1999-05-13 | 2002-12-24 | メディカル リサーチ カウンシル | Ｏｘ２レセプターホモログ |
| WO2000071581A1 (fr) * | 1999-05-20 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Nouveau polypeptide |
| AU5037100A (en) * | 1999-05-27 | 2000-12-18 | Zymogenetics Inc. | Adipocyte complement related protein homolog zacrp6 |
| US7033780B1 (en) | 1999-06-14 | 2006-04-25 | Millennium Pharmaceuticals, Inc. | Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein |
| US20030022279A1 (en) | 1999-06-14 | 2003-01-30 | Fraser Christopher C. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| IL147902A0 (en) | 1999-08-12 | 2002-08-14 | Agensys Inc | C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| AUPQ272899A0 (en) * | 1999-09-09 | 1999-09-30 | Csl Limited | Dendritic cell membrane protein fire |
| EP1230363A2 (en) * | 1999-11-19 | 2002-08-14 | ZymoGenetics, Inc. | Educational kit and method using colipase-like protein-1 |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| AU782067B2 (en) | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
| US20040086854A1 (en) * | 2001-01-12 | 2004-05-06 | Junming Yang | Drug metabolizing enzymes |
| AU2001227900A1 (en) * | 2000-01-14 | 2001-07-24 | Incyte Genomics, Inc. | Drug metabolizing enzymes |
| WO2001064837A2 (en) * | 2000-02-29 | 2001-09-07 | The General Hospital Corporation | β NETRIN AND USES THEREOF |
| AU2001245367A1 (en) * | 2000-02-29 | 2001-09-12 | Millennium Pharmaceuticals, Inc. | Human transporter genes and proteins encoded thereby |
| DE10027383A1 (de) * | 2000-06-02 | 2001-12-20 | Rhein Biotech Proz & Prod Gmbh | Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz |
| DE60136281D1 (de) * | 2000-08-24 | 2008-12-04 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| US6630325B1 (en) * | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
| EP1683865A3 (en) | 2001-02-02 | 2006-10-25 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
| US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US7186818B2 (en) * | 2001-04-26 | 2007-03-06 | Immunex Corporation | DNA encoding soluble variants of human OX2 receptors |
| US20030068636A1 (en) * | 2001-06-21 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| IL159872A0 (en) * | 2001-07-26 | 2004-06-20 | Genset Sa | Gmg-2 polypeptides and their use |
| WO2003031578A2 (en) * | 2001-10-09 | 2003-04-17 | Immunex Corporation | Mammalian c-type lectins |
| AU2002334997A1 (en) * | 2001-10-12 | 2003-04-22 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
| DE20202893U1 (de) * | 2002-02-25 | 2003-07-03 | Sachsenring Fahrzeugtechnik Gm | Vorrichtung zur Lagerung einer Kolbenverdichterbaugruppe |
| SI1482973T1 (sl) * | 2002-03-15 | 2010-01-29 | Schering Corp | Postopki za moduliranje receptorjev CD200 |
| US20040018976A1 (en) * | 2002-05-14 | 2004-01-29 | Feder John N. | Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof |
| EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
| EP1546171A4 (en) * | 2002-08-14 | 2008-01-02 | Lg Life Sciences Ltd | FAMILIES OF GENES ASSOCIATED WITH GASTRIC CANCER |
| DE10242146A1 (de) | 2002-09-04 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen |
| US8158123B2 (en) * | 2002-12-11 | 2012-04-17 | Forsyth Dental Infirmary For Children | Method of inhibiting an activity of a gene product in a bone cell encoded by a nucleotide sequence comprising SEQ ID NO: 50 |
| ES2349128T3 (es) * | 2003-02-19 | 2010-12-28 | Novartis Ag | Antigeno de glucoproteina sima 135 expresado en celulas de tumor humanas metastasicas. |
| ATE364050T1 (de) | 2003-07-24 | 2007-06-15 | Amgen Inc | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen |
| EP1652923B1 (en) | 2003-08-08 | 2011-10-12 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
| GB0324656D0 (en) | 2003-10-22 | 2003-11-26 | Celltech R&D Ltd | A protein involved in ovarian cancer |
| AU2004289252C1 (en) | 2003-11-08 | 2013-06-20 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| AU2009260822B2 (en) | 2008-05-28 | 2016-09-22 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from blood |
| AU2009325088B2 (en) * | 2008-12-10 | 2014-06-19 | Duke University | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| WO2014039987A2 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| EP3512539A4 (en) | 2016-09-13 | 2020-07-29 | Prothera Biologics, Inc. | METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS |
| BR112019022358A2 (pt) | 2017-04-25 | 2020-05-19 | Prothera Biologics Inc | métodos para quantificar proteínas inibidoras inter-alfa |
| CN109324189B (zh) * | 2018-08-15 | 2021-10-01 | 泰达国际心血管病医院 | 多蛋白组合物的应用及先天性心脏病筛查试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4543252A (en) * | 1982-01-21 | 1985-09-24 | The Regents Of The University Of California | Cationic oligopeptides having microbicidal activity |
| US5091303A (en) * | 1989-10-27 | 1992-02-25 | The General Hospital Corporation | Diagnosis of wegener's granulomatosis |
| US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
| US5837490A (en) * | 1996-06-17 | 1998-11-17 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US5807703A (en) * | 1996-06-17 | 1998-09-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US5827688A (en) * | 1996-06-17 | 1998-10-27 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1998017795A1 (en) * | 1996-10-25 | 1998-04-30 | Cedars-Sinai Medical Center | Nucleic acid encoding ds-cam proteins and products related thereto |
| US5843727A (en) * | 1997-04-08 | 1998-12-01 | Incyte Pharmacuticals, Inc. | Polynucleotides encoding a human tumor-associated membrane protein |
-
1999
- 1999-07-29 AU AU51347/99A patent/AU5134799A/en not_active Abandoned
- 1999-07-29 JP JP2000562480A patent/JP2002521055A/ja active Pending
- 1999-07-29 WO PCT/US1999/017130 patent/WO2000006698A1/en not_active Ceased
- 1999-07-29 EP EP99935985A patent/EP1100869A4/en not_active Withdrawn
- 1999-07-29 CA CA002339301A patent/CA2339301A1/en not_active Abandoned
-
2000
- 2000-01-24 US US09/489,847 patent/US6476195B1/en not_active Expired - Fee Related
-
2005
- 2005-09-20 US US11/229,769 patent/US20060079670A1/en not_active Abandoned
-
2007
- 2007-07-12 US US11/777,133 patent/US20080051338A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1100869A1 (en) | 2001-05-23 |
| EP1100869A4 (en) | 2005-04-27 |
| US20080051338A1 (en) | 2008-02-28 |
| WO2000006698A1 (en) | 2000-02-10 |
| US6476195B1 (en) | 2002-11-05 |
| AU5134799A (en) | 2000-02-21 |
| US20060079670A1 (en) | 2006-04-13 |
| JP2002521055A (ja) | 2002-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2339301A1 (en) | Hdpbo81 nucleic acids and polypeptides | |
| Mizejewski | β-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure | |
| US7169565B2 (en) | Antibodies to HASAV70 polypeptide | |
| CA2331154A1 (en) | Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor | |
| US20030055236A1 (en) | Secreted protein HKABT24 | |
| CA2332109A1 (en) | 97 human secreted proteins | |
| CA2291260A1 (en) | 207 human secreted proteins | |
| US6531447B1 (en) | Secreted protein HEMCM42 | |
| US7217528B2 (en) | Antibodies to HFXJW48 polypeptide | |
| CA2323761A1 (en) | 95 human secreted proteins | |
| JP2002501738A (ja) | ６７個のヒト分泌タンパク質 | |
| CA2333917A1 (en) | 71 human secreted proteins | |
| CA2308768A1 (en) | 125 human secreted proteins | |
| CA2372926A1 (en) | 143 human secreted proteins | |
| JP2003521903A (ja) | Ｃｄ８４様ポリペプチドおよびポリヌクレオチドに関する方法と材料 | |
| CA2307320A1 (en) | 148 human secreted proteins | |
| JP2001517943A (ja) | ヒト膵炎関連タンパク質、ｐａｐ−２ | |
| US20030105297A1 (en) | Secreted protein HEMCM42 | |
| JP2005510240A (ja) | ヒトｃＤＮＡ及びタンパク質及びその使用 | |
| US20030144492A1 (en) | 101 human secreted proteins | |
| CA2298852A1 (en) | 83 human secreted proteins | |
| CA2321970A1 (en) | 36 human secreted proteins | |
| CA2383690A1 (en) | 29 human secreted proteins | |
| US20050214844A1 (en) | 86 human secreted proteins | |
| CN100443501C (zh) | 人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130821 |